Comparing BetterLife Pharma (OTCMKTS:BETRF) & Dyne Therapeutics (NASDAQ:DYN)

Dyne Therapeutics (NASDAQ:DYN) and BetterLife Pharma (OTCMKTS:BETRF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability.

Earnings & Valuation

This table compares Dyne Therapeutics and BetterLife Pharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21 million	($3.54)	-5.06
BetterLife Pharma	N/A	N/A	-$2.55 million	N/A	N/A

Volatility & Risk

Dyne Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, BetterLife Pharma has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.

Insider and Institutional Ownership

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 0.0% of BetterLife Pharma shares are held by institutional investors. 14.1% of Dyne Therapeutics shares are held by insiders. Comparatively, 34.8% of BetterLife Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Dyne Therapeutics and BetterLife Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1	2	11	3	2.94
BetterLife Pharma	0	0	0	0	0.00

Dyne Therapeutics presently has a consensus price target of $35.14, indicating a potential upside of 96.11%. Given Dyne Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Dyne Therapeutics is more favorable than BetterLife Pharma.

Profitability

This table compares Dyne Therapeutics and BetterLife Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-61.46%	-50.94%
BetterLife Pharma	N/A	N/A	-764.44%

Summary

Dyne Therapeutics beats BetterLife Pharma on 7 of the 10 factors compared between the two stocks.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

About BetterLife Pharma

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.